Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasimelteon in Pediatric Insomnia
NCT06953869Phase 3Recruiting
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Apr 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of tasimelteon in insomnia disorder, sponsored by Vanda Pharmaceuticals Inc.. Started Apr 2025; status: recruiting.
02
Drugs
tasimelteon
03
Conditions
insomnia disorder
Beyond the preview
Go deeper on NCT06953869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06953869.